Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bothrops phospholipases A2 (PLA2s) are a diverse group of enzymes found in the venom of pit vipers belonging to the Bothrops genus, which are responsible for the majority of snakebite accidents in Latin America (Gutiérrez & Lomonte, 2013). These enzymes primarily function by hydrolyzing the sn-2 ester bond of glycerophospholipids, leading to the release of fatty acids and lysophospholipids that disrupt cell membranes and trigger inflammatory cascades (Lomonte et al., 2009). In the context of envenomation, Bothrops PLA2s induce severe local effects such as myonecrosis, edema, and hemorrhage, as well as systemic effects like anticoagulation and neurotoxicity (Fernandes et al., 2014). While traditional treatment relies on equine-derived antivenoms, these often fail to neutralize the local tissue damage effectively due to the rapid action of PLA2s (Gutiérrez et al., 1998). Consequently, these enzymes have become critical targets for small-molecule inhibitors like Varespladib, which aim to provide early intervention and reduce the morbidity associated with snakebites (Lewin et al., 2016). Understanding the structural diversity of these enzymes, including both catalytically active (Asp49) and inactive but toxic (Lys49) variants, is essential for developing broad-spectrum therapeutics (UniProt, 2024).
Inhibitors like Varespladib act as competitive antagonists that bind to the active site of the PLA2 enzyme, specifically interacting with the catalytic residues (e.g., His48, Asp49) and the calcium-binding loop, thereby preventing the binding and hydrolysis of phospholipid substrates and the subsequent release of inflammatory mediators (Lewin et al., 2016; PubChem, 2024).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bothrops phospholipase A2 (PLA2).